Navigation Links
Research finds novel airborne germ-killing oral spray effective in fighting colds and flu
Date:9/9/2012

University Hospitals Case Medical Center clinical researchers will present findings about a one-two punch to prevent colds and flu in San Francisco at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on Sept. 9.

The research team is presenting data in two poster presentations that a new oral antiseptic spray is effective in killing 99.9 percent of infectious airborne germs. Findings from these two presentations led to the development of Halo Oral Antiseptic, a first-of-its kind germ-fighting spray which is currently on store shelves.

"Respiratory tract disease is a major cause of morbidity and mortality throughout the world," says Frank Esper, MD, infectious disease expert at UH Rainbow Babies & Children's Hospital and lead author of one of the studies. "Yet there has been limited progress in the prevention of respiratory virus infections. Halo is unique in that it offers protection from airborne germs such as influenza and rhinovirus."

Dr. Esper and a team of researchers used glycerine and xanthan gum as a microbial barrier combined with cetylpyridinium chloride (CPC) as a broad-spectrum anti-infective agent to fight respiratory illnesses. To test this, clinical strains of 2009 pandemic H1N1 were used as a prototype virus to demonstrate Halo's anti-infective activity in cell culture assays. "The glycerine and xanthan gum prevent the germs from entering a person's system and the CPC kills the germs once they're trapped there," explains Dr. Esper, who is also Associate Professor at Case Western Reserve University School of Medicine.

Dr. Esper will present his findings that Halo will have clear benefit to aid against infection and reduce disease from epidemic, sporadic or pandemic respiratory viral infections, particularly helping people at risk for severe respiratory illness including immune-compromised individuals with chronic lung disease, and military personnel.

Another study on Halo will be presented by Mahmoud Ghannoum, PhD, of UH Case Medical Center, showing Halo's effectiveness against disease-causing pathogenic germs. The presentation asserts that respiratory and/or systemic infections through airborne and manually transmitted pathogenic microbes often enter the system through the mouth, making Halo, an oral spray that targets these pathogens, an effective way to prevent infections. Additionally, preliminary data from the researchers found that Halo completely kills all 11 clinical strains of whooping cough (Bordetella pertussis) against which the spray was tested.

The results showed that when a person used three sprays of Halo, it destroyed airborne germs breathed in for up to six hours, even when people were eating and drinking. The concept of coating the back of the oral cavity to prevent germs from entering and then providing sustained antiseptic action to kill airborne germs was developed by a Cleveland company, Oasis Consumer Healthcare.

"Exposure to airborne germs is inevitable especially in crowded environments and when traveling," said Dr. Ghannoum, who is also the Director of the Center for Medical Mycology at Case Western Reserve University School of Medicine. "Unlike other products that support the immune system or protect from germs on surfaces or hands, Halo is the first and only product of its kind to offer protection from airborne germs."


'/>"/>

Contact: Alicia Reale
alicia.reale@uhhospitals.org
University Hospitals Case Medical Center
Source:Eurekalert

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. Research reveals first evidence of hunting by prehistoric Ohioans
3. Diabetes Research Institute develops oxygen-generating biomaterial
4. APS issues new policy requiring identification of sex or gender in reporting scientific research
5. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
6. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
7. U of Alberta researcher steps closer to understand autoimmune diseases
8. Research on flavanols and procyanidins provides new insights into how these phytonutrients may positively impact human health
9. A project to research biological and chemical aspects of microalgae to fuel approach
10. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
11. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... DIEGO , Jan. 12, 2017  Trovagene, Inc. ... tumor DNA (ctDNA) technologies, today announced that it has ... Europe and the Middle East ... tests.  This milestone marks the first wave of international ... for urine and blood samples. The initial ...
(Date:1/11/2017)... Johnson, co-founder of Visikol Inc. a company originally funded with an ... the elite "Forbes 30 Under 30" list in the Science category. ... fields nationwide to be recognized as a leader in business and ... ... PhD candidate at Rutgers University. Visikol , ...
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at this ... leader in connected health and biometric measurement devices and services, will be ... On display in A&D Medical,s special CES Exhibit Suite , ... ongoing expansion of the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, which ... it has submitted a 510(k) to the FDA, requesting clearance of the MyoCycle ... electrical stimulation (FES) technology. , The submission marks a major milestone for ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... Summit for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join ... clinical research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, ...
(Date:1/18/2017)... CA (PRWEB) , ... January 18, 2017 , ... ... report the publishing of the latest paper by its Science Editor, Dr. Elisabeth ... (Nederlands Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from ...
(Date:1/18/2017)... Jan. 18, 2017 Shareholder rights law firm ... whether the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... connection with the proposed sale of the Company to ... that develops small molecules for the acute treatment of ... it had signed a definitive merger agreement with Eli ...
Breaking Biology Technology: